Dong-A likely to commercialize new second-generation oxazolidinone antibiotic

Published: 2012-01-25 06:58:00

Updated: 2012-01-25 06:58:00

Dong-A Pharmaceutical Co. announced Thursday the positive results of its new second-generation oxazolidinone antibiotic (tedizolid phosphate; DA-7218) from the first Phase 3 clinical trial in acute bacterial skin and skin structure infections, heralding the possible development of a global new drug.

The U.S. based Trius Therapeutics, who entered into a license agreement with Dong-A in Februa...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.